

Thomas Jefferson University Jefferson Digital Commons

Phase 1

Class of 2023

2-2021

Tumor Doubling Time of Pulmonary Carcinoid Tumors Measured by CT

Douglas Russ

Julie Barta, MD

Nathaniel R. Evans, MD

Robert T. Stapp, DO

Gregory C. Kane, MD

Follow this and additional works at: https://jdc.jefferson.edu/si_ctr_2023_phase1

Part of the Translational Medical Research Commons
<u>Let us know how access to this document benefits you</u>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.




Tumor Doubling Time of Pulmonary Carcinoid Tumor Measured by CT

Douglas H Russ, BS, Julie A Barta, MD, Nathaniel R Evans, MD, Robert T Stapp, DO, Gregory C. Kane, MD*



Background

- Pulmonary Carcinoid Tumor (PCT) is a neuroendocrine neoplasm
- 1-2% of all lung cancers
- Typical (low grade) and atypical (intermediate grade) subtypes
- Metastatic, but indolent
 - Clinically known to grow slowly, but limited literature on growth rates
- Often identified as solitary nodules on incidental radiography (e.g. CXR, Chest CT)



Phillipe Joubert, MD, PhD



Background

• What to do once incidental nodule is identified?

Fleischner Society 2017 Guidelines for Management of Incidentally Detected Pulmonary Nodules in Adults A: Solid Nodules* Size <6 mm ($<100 \text{ mm}^{3}$) 6-8 mm (100-250 mm³) Nodule Type >8 mm (>250 mm³) Comments Single Low risk[†] No routine follow-up CT at 6–12 months, then Consider CT at 3 months. PET/CT. Nodules <6 mm do not require routine follow-up in low-risk patients (recommendation 1A). consider CT at or tissue sampling 18-24 months

• If PCT is truly slow-growing, is a 2-year follow up timeframe long enough to detect tumor growth on CT?



at Thomas Jefferson

MR, 78 y.o. male

Chest CT for Hx of bronchiectasis → incidental **5 mm peripheral nodule** visible

01-200 11-2007 Repeat CT → not

09-2017

Percutaneous needle biopsy of nodule now measuring **10 mm**



Objectives & Hypothesis

- Research Question
 - What is the true growth rate of PCT as measured on CT?
- Hypothesis
 - We hypothesized that PCT would demonstrate a prolonged tumor doubling time compared to other lung neoplasms.





- Retrospective medical chart review
- Medical charts (EPIC) & radiographic scans (PACS)
- PCT nodule dimensions measured manually or retrieved from radiology reports
- Inclusion criteria
 - Pathologic diagnosis of PCT
 - ≥ 2 years of radiographic follow up by CT prior to biopsy/resection
 - Tumor demonstrated definitive growth*
- 14/89 patients with pathologically-confirmed PCT met all criteria
- 11 typical carcinoids, 3 atypical carcinoids

*defined as an increase in average nodule diameter ≥ 2 mm¹



Results: Tumor Doubling Time


Volume Doubling Time¹ = $[\ln 2 \times \Delta T] / [\ln(V_2/V_1)] = \Delta T / [\log_2(V_2/V_1)]$

Patient MR → **171 weeks**

11 typical PCTs demonstrated definitive growth

Median DT = 140 weeks Mean DT = 161 ± 105

SCLC² \rightarrow 6 weeks SCC² \rightarrow 13 weeks Adenocarcinoma² \rightarrow 20 weeks (solid), 36 weeks (subsolid)





Conclusions

- The median doubling time of typical PCT was 141 weeks, or almost three years.
- The frequency of atypical carcinoids was too small to form any conclusion about growth rates.
- It is conceivable that typical PCTs detected early with small diameter may be mistaken for benign non-growing lesions when followed for less than two years in low-risk patients.



Future Directions

• Analysis of larger, prospective cohorts could identify the frequency of PCT and other tumors with prolonged doubling time compared with non-neoplastic lung nodules.



Acknowledgements

- Dr. Gregory Kane
- Dr. Julie Barta





- 1. Bell, Botz et al. "Tumor doubling time." Radiopaedia.org. <u>https://radiopaedia.org/articles/volume-doubling-time?lang=us</u>
- 2. Bankier, et al. "Recommendations for Measuring Pulmonary Nodules at CT: A statement from the Fleischner Society." November, 2017.
- 3. Henschke, et al. "Lung Cancers Diagnosed at Annual CT Screening: Volume Doubling Times." Thoracic Imaging. May, 2012.